Last reviewed · How we verify
NCT03527784
Prestoma-Trial for Parastomal Hernia Prevention
NA trial testing Parietene Macro in Rectal Adenocarcinoma in 14 participants. Terminated before completion.
29 October 2018
Quick facts
| Lead sponsor | University of Oulu |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 14 |
| Start date | 3 May 2018 |
| Primary completion | 29 October 2018 |
| Estimated completion | 29 October 2018 |
| Sites | 6 locations across Finland |
Drugs / interventions tested
- Parietene Macro
- Parietex Parastomal
- Dynamesh IPST
Conditions studied
- Rectal Adenocarcinoma — all drugs for Rectal Adenocarcinoma →
Sponsor
University of Oulu
Who can join
18 and older, any sex, with Rectal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prestoma Trial is designed to compare the safety and efficiency of three different meshes and techniques to prevent parastomal hernia after laparoscopic or robotic-assisted abdominoperineal resection for rectal adenocarcinoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03527784
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rectal Adenocarcinoma
Currently open trials in the same condition.
- NCT07407465 — Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal · Phase 2 · recruiting
- NCT07198165 — SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC · Phase 2 · recruiting
- NCT06997497 — A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-108 · Phase 3 · recruiting
- NCT06780787 — FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery · Phase 2 · recruiting
- NCT06908031 — SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer · Phase 2 · recruiting
Other University of Oulu trials
Trials by the same sponsor.
- NCT07381933 — The Effect of Consumed Berries on Extracellular Vesicle Signalling in the Body · NA · recruiting
- NCT07280624 — Diagnostic PCR Panel in Children With Acute Gastrointestinal Symptoms · NA · not yet recruiting
- NCT05494684 — Effectiveness of Multisensoral Nature-based Intervention in Hospitalized Children During Venous Blood Sampling · NA · not yet recruiting
- NCT06711393 — The Effectiveness of Exergaming for Older People Mobility and Balance · NA · not yet recruiting
- NCT06171867 — PNEUMACRIT Device for Neonatal Cardio Respiratory Monitoring · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03527784 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Oulu
- Last refreshed: 5 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03527784.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing